Study: A Phase II study of Bladder SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3 Node PosItive BladdeR CancEr (INSPIRE)
Clinical Trial #: EA8185
NCT Number: NCT04216290
Principal Investigator: Dr. David VanderWeele
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Chemoradiotherapy with or w/o Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer.
Clinical Trial #: S1806
NCT Number: NCT03775265
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Clinical Trial #: S1925
NCT Number: NCT04269902
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Clinical Trial #: EAA173
NCT Number: NCT03937635
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577
NCT #: NCT00887146
Principal Investigator: Dr. Kumthekar
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastoma
Clinical Trial #: NU 21C01
NCT#: NCT05236036
Principal Investigator: Dr. Kumthekar
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Clinical Trial #: NRG-BN012
NCT#: NCT05438212
Principal Investigator: Dr. Magill
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Safety and tolerability of MW151 administered with hippocampal avoidant whole brain radiation therapy (HA-WBRT) in patients with brain metastases
Clinical Trial #: MW151-102 ImmunoChem
NCT#: NCT05417282
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Clinical Trial #: NRG-CC009
Principal Investigator: Dr. Sachdev
Contact: Research Office 630.933.7820
Study: A Phase 2, single arm, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Clinical Trial #: NU 16C02
NCT#: NCT02847559
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Clinical Trial #: SAPIENCE ST101-101
NCT#: NCT04478279
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Study: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Clinical Trial #: NRG-BN007
NCT #: NCT04396860
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Clinical Trial #: EAF151 20-062
NCT #: NCT03115333
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Clinical Trial #: NRG-BN009
NCT #: NCT04588246
Principal Investigator: Dr. Gondi
1
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Clinical Trial #: NU18C02
NCT #: NCT04047706
Principal Investigator: Dr. Buerki
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
NCT #: NCT03180502
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
NCT #: NCT02834013
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov2
Study: A Phase III Clinical Trial Evaluating De-escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)
Clinical Trial #: NRG-BR007
NCT #: NCT04852887
Principal Investigator: Dr. Donnelly
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Clinical Trial #: S2007
NCT#: NCT04647916
Principal Investigator: Dr. Ami Shah
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
Clinical Trial #: TOL2506 OVELIA 21-041
NCT#: NCT04906395
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE,
Clinical Trial #: EA1183 22-003
NCT#: NCT04316117
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801 22-011
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
Clinical Trial #: NU 15B06
NCT Number: NCT02694809
Principal Investigator: Mary Ahn, MD
Contact: Research Office 630.352.5362
Learn more at Clinicaltrials.gov
Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Clinical Trial #: A021502
NCT Number: NCT02912559
Principal Investigator: Dr. Dawravoo
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Clinical Trial #: NRG GI005
NCT Number: NCT04068103
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Clinical Trial #: NRG-GI008
NCT Number: NCT05174169
Principal Investigator: Dr. Mary Mulcahy
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT#: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Clinical Trial #: EA2197
NCT#: NCT04559139
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Renal
Study: A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or Without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
Clinical Trial #: S2200
NCT #: NCT05411081
Principal Investigator: Dr. Shenoy
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Clinical Trial #: S1931
NCT Number: NCT04510597
Principal Investigator: Dr. Jeffrey Sosman
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Clinical Trial #: NRG-GU012
NCT Number: NCT05327686
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office (630) 933-7820
Learn more at Clinicaltrials.gov
Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT Number: NCT04671667
Principal Investigator: Dr. Jochen Lorch
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
NCT Number: NCT02194738
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Clinical Trial #: E4512
NCT Number: NCT02201992
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
Clinical Trial #: Protocol RTOG1308
Principal Investigator: Vinai Gondi, MD
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Squamous Cell Carcinoma
Study: A Randomized Phase II Study of De-Intensified ChemoRadiation for EarlyStage Anal Squamous Cell Carcinoma (DECREASE)
Clinical Trial #: EA2182
NCT #: NCT04166318
Principal Investigator: Dr. Kircher
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Metastatic Urothelial Carcinoma
Study: A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Clinical Trial #: S1937
NCT #: NCT04579224
Principal Investigator: Dr. Fenton
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Myelodysplastic Syndromes
Study: he National Myelodysplastic Syndromes (MDS) Study
Clinical Trial #: NHLBI-MDS
NCT#: NCT02775383
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Oropharyngeal Cancer
Study: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Clinical Trial #: NRG-HN005
NCT Number: NCT03952585
Principal Investigator: Dr. Gharzai
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Colorectal Cancer
Study: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Clinical Trial #: A221805
NCT Number: NCT04137107
Principal Investigator: Dr. Abad
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Mantle Cell Lymphoma
Study: A randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Clinical Trial #: EA4151
NCT Number: NCT03267433
Principal Investigator: Robert Eisner, DO
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Multiple Myeloma
Study: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Clinical Trial #: EAA181
NCT Number: NCT04566328
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Recurrent Tumors Previously Treated with Radiation Therapy
Study: Retreatment of non-CNS solid malignancies. Treatment sites: head & neck, thorax, pelvis, abdomen, extremities.
Clinical Trial #: UPCC 23309
Principal Investigator: William Hartsell, MD
Learn more at Clinicaltrials.gov
Pediatric Proton Consortium Registry (PPCR)
Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Rare Tumors
Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Christopher George, MD
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Registry
Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD
Learn more at Clinicaltrials.gov
Cross-disease sites
Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad
Study: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Clinical Trial #: S2104
NCT #: NCT05040360
Principal Investigator: Dr. Mulcahy
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Clinical Trial #: A021806
NCT Number: NCT04340141
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Clinical Trial #: PAN009-18
NCT Number: NCT02598349
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Evaluating the Response to Neoadjuvant Chemotherapy with Circulating Tumor DNA in Pancreatic Cancer
Clinical Trial #: ctDNA
NCT Number: NCT04616131
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Clinical Trial #: EA2186
NCT Number: NCT04233866
Principal Investigator: Kevin Dawravoo, MD
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Clinical Trial #: EA2185
NCT Number: NCT04239573
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Clinical Trial #: PCG-GU010-18
NCT #: NCT00969111
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Clinical Trial #: NRG-GU009
NCT#: NCT04513717
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Study of Image Guided Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
Clinical Trial #: GU003-10
NCT#: NCT01492972
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Clinical Trial #: NRG-GU010
NCT#: NCT05050084
Principal Investigator: Sean Sachdev
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Clinical Trial #: EA8191
NCT#: NCT04423211
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes (PROMISE)
Clinical Trial #: C19-235
NCT #: NCT04995198
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)
NCT #: NCT04493853
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Clinical Trial #: PARTIQoL
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Study: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Clinical Trial #: S2015
Principal Investigator: Dr. Wayne
Contact: Research Office 630.933.7820
Endometrial
Study: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
Clinical Trial #: NRG-GY012
NCT #: NCT03660826
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Endometrial
Study: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Clinical Trial #: GY018
NCT #: NCT03914612
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Endometrial
Study: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Clinical Trial #: NRG-GY026
NCT #: NCt05256225
Principal Investigator: Emily Hinchcliff
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Ovarian
Study: A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Clinical Trial #: NRG-GY023 / 22-013
NCT #: NCT04739800
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Ovarian
Study: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Clinical Trial #: NRG-CC008
NCT #: NCT04251052
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov
Ovarian or Peritoneum
Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820
Learn more at Clinicaltrials.gov